An Ultrasound examination was only performed,
showing sospicious hypoechoic mass in all cases.
A needle biopsy was executed to all patients.
PATIENT
|
ONSET
|
GESTATION WEEK
|
HYSTOLOGY
|
BIOLOGY
|
METASTASES AT ONSET
|
TREATMENT
|
FOLLOW-UP (2 years)
|
M.D.
32Y
|
Carcinomatous mastitis left breast
|
27
|
Ductal invasive carcinoma
|
RE: 90%; RP:5%;Ki67: 74%;
Her2: +++
|
Liver and bones
|
CT Neoadiuvant (cyclophosphamide and Epyrubicin) till delivery at 36° week.
Then CT adjuvant with Pertuzumab,
Trastuzumab and Docetaxel.
|
Breast complete response with
Stable disease
|
T.L.
32Y
|
2 cm Left breast palpable lump
|
20°
|
Ductal invasive carcinoma
|
RE: 1%; RP: 1%; ki67: 36%; Her2: +++
|
Lymph nodes
|
CT Neoadiuvant (cyclophosphamide and Epyrubicin) till delivery at 36° week.
Then CT adjuvant with Herceptin plus Taxolo
|
Pathologic Complete Response
|
L.A.
30Y
|
3 cm right breast palpable lump
|
20°
|
Ductal invasive carcinoma
|
RE: 90%; RP: 80%; ki67: 23%;
Her2: ++);
|
|
Right mastectomy with axyllary limphnode dissection at 25° week.
Delivery at 37° week and CT adjuvant with Epyrubicin
|
Pathologic Complete Response
|
A.S.
35Y
|
Carcinomatous mastitis right breast
|
25°
|
Ductal invasive carcinoma
|
RE: 80%; RP:5%;
Ki67: 65%; Her2: +++
|
|
CT Neoadiuvant (cyclophosphamide and Epyrubicin) till delivery at 36° week.
Then CT adjuvant with Pertuzumab,
Trastuzumab and Docetaxel.
|
Pathologic Complete Response
|
V.A.
30Y
|
2 cm Left breast palpable lump
|
21°
|
Ductal invasive carcinoma
|
RE: 1%; RP: 1%; ki67: 36%; Her2: +++
|
|
CT Neoadiuvant (cyclophosphamide and Epyrubicin) till delivery at 36° week.
Then CT adjuvant with Herceptin plus Taxolo
|
Pathologic Complete Response
|
S.S.
28Y
|
2 cm right breast palpable lump
|
19°
|
Ductal invasive carcinoma
|
RE: 80%; RP: 85%; ki67: 20%;
Her2: ++
|
|
Right mastectomy with axyllary limphnode dissection at 25° week.Delivery at 37° week and CT adjuvant with Epyrubicin
|
Pathologic Complete Response
|